These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22120734)

  • 1. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
    Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
    Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
    Willrich MA; Rodrigues AC; Cerda A; Genvigir FD; Arazi SS; Dorea EL; Bernik MM; Bertolami MC; Faludi A; Largura A; Baudhuin LM; Bryant SC; Hirata MH; Hirata RD
    Clin Chim Acta; 2013 Jun; 421():157-63. PubMed ID: 23501331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
    Kadam P; Ashavaid TF; Ponde CK; Rajani RM
    J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
    Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
    Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
    Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
    Willrich MA; Hirata MH; Genvigir FD; Arazi SS; Rebecchi IM; Rodrigues AC; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata RD
    Clin Chim Acta; 2008 Dec; 398(1-2):15-20. PubMed ID: 18727922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
    Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
    Am J Cardiol; 2004 Jan; 93(1):104-7. PubMed ID: 14697480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.
    Rodrigues AC; Rebecchi IM; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
    Braz J Med Biol Res; 2005 Sep; 38(9):1389-97. PubMed ID: 16138223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
    Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
    Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
    Jiang XY; Zhang Q; Chen P; Li SY; Zhang NN; Chen XD; Wang GC; Wang HB; Zhuang MQ; Lu M
    J Clin Pharm Ther; 2012 Dec; 37(6):719-23. PubMed ID: 22882727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Willrich MA; Arazi SS; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
    Lipids Health Dis; 2011 Nov; 10():206. PubMed ID: 22074026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
    Gao Y; Zhang LR; Fu Q
    Eur J Clin Pharmacol; 2008 Sep; 64(9):877-82. PubMed ID: 18528690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
    Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
    Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
    Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
    Atherosclerosis; 2005 Jun; 180(2):407-15. PubMed ID: 15910869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
    Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals.
    Cuevas A; Fernández C; Ferrada L; Zambrano T; Rosales A; Saavedra N; Salazar LA
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):292-7. PubMed ID: 26408409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.